Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SPARC.NS
Strong BuyFull HouseSun Pharma Advanced Research Company Limited · Healthcare · India · $696M · Avg Vol: $2M/d
89
StockRankGet insider-trade alerts
Q
68
V
60
M
60
P/E (TTM)
4.1x
ROE
116.0%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2.4B | 755.5M | 717.7M | 391.5M | -45.3% | 19.1B |
| EPS (INR) | -7.82 | -11.93 | -10.55 | 47.86 | — | 48.83 |
| Shares | 324.5M | 324.5M | 324.5M | 324.5M | 0.0% | 324.5M |
| Debt | 156.8M | 576.6M | 2.7B | 5.6B | 228.9% | 5.6B |
| Equity | 5.1B | 1.3B | -2.2B | 13.4B | 37.7% | — |
| Op CF | -691.2M | -4.3B | -3.6B | -2.4B | — | -2.4B |
| Inv CF | -5.5B | 3.9B | 1.6B | -235.0M | — | — |
| Fin CF | 6.2B | 424.1M | 2.0B | 2.6B | — | — |
Loading 1Y...
PRICE (1Y)-3.8%
SMA 50SMA 200
Close
$2.11
RSI (14)
51.0
52W High
$3.04
From 52W High
0.7%
SCORE BREAKDOWN
Quality
68
ROIC
114.4%99.8
ROE
116.0%99.5
GP/Assets
86.5%96.9
Op. Margin
-90.7%17.5
FCF/Assets
-12.1%27.5
Piotroski
668.8
Int. Cover
44.9x77.8
D/E Ratio
0.42x33.0
Current Ratio
2.47x47.7
Value
60
P/E (TTM)
4.1x98.4
EV/EBITDA
4.4x94.1
P/FCF
—N/A
P/B
4.9x29.5
P/S
3.4x52.6
Div Yield
—N/A
Momentum
60
52W High %
69%48.0
RS 6M
64%93.1
SMA 50/200
1.28x92.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+13%29.8
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$696M
P/E (Forward)
3.6x
Gross Margin
98.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SPARC.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SPARC.NS | Sun Pharma Advanced Research Company Limited(you) | $696M | 89 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $653M | 89 | Strong Buy |
| MOREPENLAB.NS | Morepen Laboratories Limited | $677M | 85 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $810M | 87 | Strong Buy |
| PGHL.NS | Procter & Gamble Health Limited | $981M | 92 | Strong Buy |
| INNOVACAP.NS | Innova Captab Limited | $707M | 79 | Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
| STAR.NS | Strides Pharma Science Limited | $1.2B | 93 | Strong Buy |
| FDC.NS | FDC Limited | $594M | 76 | Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%